Disclosure: Vital Signs Today may earn a commission if you buy through links on this page, at no extra cost to you. This does not influence our evidence-based assessments. We are not a medical provider; talk to a clinician before acting on test results.
Educational content, not medical advice. Talk to a licensed clinician before starting any peptide therapy.
Short answer: Peptides work by binding to specific receptor proteins on cell surfaces and triggering intracellular signaling cascades that change what a cell does, produces, or stops producing. A 29-amino-acid GLP-1 peptide, for instance, binds its receptor in hindbrain neurons and suppresses dopamine reward signaling, which is why semaglutide reduces hunger even when you think about food. The biology is precise, the effects are real, and the mechanism varies completely depending on which peptide you are talking about.
Most coverage of peptides stops at “they signal your cells.” That is accurate the way “cars move when you press the gas” is accurate. It tells you nothing about what is actually happening. This article goes one layer deeper, because if you understand the mechanism, you understand why a subcutaneous injection of sermorelin behaves nothing like an oral collagen supplement, and why BPC-157’s regulatory status changed overnight in April 2026.
What Exactly Is a Peptide, and How Is It Different from a Protein?
A peptide is a chain of amino acids linked by peptide bonds, typically defined as fewer than 50 amino acids in length. Proteins are longer chains, usually folded into complex three-dimensional structures. The distinction matters because size determines how your body processes and absorbs each molecule.
Small peptides (2-10 amino acids) can cross intestinal epithelial cells intact via PepT1 and PepT2 transporter proteins. Larger peptides and proteins cannot survive oral transit without protection because stomach acid and proteases digest them. That is why insulin has never worked as a pill despite 100 years of trying, and why peptide delivery engineering is one of the most active areas in pharmaceutical research right now.
Insider insight: most “oral peptide supplements” marketed as healing or anabolic rely on very short oligopeptides (di- and tripeptides) or degraded fragments. When a company says their product delivers “bioactive peptides,” it usually means the peptides survive digestion as fragments, not intact molecules. The biological activity of those fragments may or may not resemble the parent molecule.
How Does a Peptide Actually Bind a Receptor?
Receptor binding is a lock-and-key interaction, but that metaphor undersells the precision. Every receptor has an extracellular binding domain with a specific three-dimensional shape. A peptide must match that shape closely enough to dock, change the receptor’s conformation, and activate whatever signaling protein is attached to the receptor’s intracellular tail.
The three main receptor families that peptides act on are:
G protein-coupled receptors (GPCRs): The largest receptor superfamily in the human genome, with over 800 members. When a peptide binds a GPCR, the G protein inside the cell activates one of several second-messenger cascades: cAMP (via adenylate cyclase), IP3/DAG (via phospholipase C), or others. GLP-1, glucagon, PTH, oxytocin, and many other signaling peptides work through GPCRs.
Receptor tyrosine kinases (RTKs): Insulin and IGF-1 bind RTKs. When the peptide docks, the receptor’s intracellular portion phosphorylates specific tyrosine residues, triggering downstream signaling through PI3K/Akt and MAPK/ERK pathways. These pathways control cell growth, glucose uptake, and protein synthesis.
Cytokine receptors: Peptides like thymosin alpha-1 engage JAK-STAT pathways, shifting immune cell gene expression. Thymosin alpha-1 is FDA-approved as Zadaxin and has a 32-year clinical dataset for immune modulation.
The key point: binding one receptor does not simply turn on one effect. It activates a cascade that branches into dozens of downstream targets depending on cell type, co-receptor expression, and existing cellular state. That is why semaglutide affects not just appetite but also inflammation, liver fat, and cardiovascular risk simultaneously.
Full-body lab membership: 100+ biomarkers, doctor-reviewed, tracked over time.
Why Does Delivery Method Change Everything?
Peptide bioavailability depends entirely on whether the molecule reaches its target receptor intact. The four main delivery routes have completely different outcomes:
Subcutaneous injection: Deposits the peptide into adipose tissue, where it diffuses into capillaries and enters systemic circulation. Bioavailability is typically 80-99% for small peptides. This is the gold standard for peptides larger than about 15 amino acids.
Intravenous injection: 100% bioavailability by definition, but only used clinically because it requires sterile technique and bypasses all absorption barriers. Not practical for outpatient use.
Intranasal: Bypasses the blood-brain barrier partially, relevant for peptides targeting CNS receptors. PT-141 (bremelanotide) was originally developed intranasally before the subcutaneous formulation was approved.
Oral: Only works reliably for very short peptides or specially engineered formulations. Oral semaglutide (Wegovy oral version, approved December 2025) uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as an absorption enhancer. SNAC transiently increases gastric pH and facilitates transcellular absorption of the intact semaglutide molecule. Even with SNAC, oral semaglutide achieves only about 1% bioavailability compared to subcutaneous — which is why the oral dose (50 mg) is dramatically higher than the injectable dose (2.4 mg for weight loss).
Insider insight: a peptide that “worked in studies” does not mean the oral supplement version works. Most collagen peptides work because hydrolyzed collagen fragments ARE short enough to absorb (di- and tripeptides). GLP-1 receptor agonists work orally only with pharmaceutical-grade absorption engineering. Assuming oral = injectable is the single most common misunderstanding in the peptide space.
How Do GLP-1 Peptides Work for Weight Loss?
The standard explanation is that GLP-1 peptides reduce hunger and slow gastric emptying. That is true but it misses where the weight-loss signal actually originates.
GLP-1 receptors are expressed throughout the body: pancreatic beta cells, gut enteroendocrine cells, vagal afferent neurons, and most importantly for weight loss, the central nervous system. Specifically, the nucleus tractus solitarius (NTS) in the hindbrain, the area postrema (AP), and the hypothalamic nuclei (arcuate ARC and paraventricular PVH).
When semaglutide reaches the NTS and AP, it does two things: it amplifies satiety signals from the gut, and it suppresses dopamine reward signaling in the mesolimbic pathway. The second mechanism is why people on GLP-1 agonists report that food, alcohol, and even gambling become less compelling. The drug is not just making your stomach feel full — it is quieting the reward drive that makes you want food in the first place.
Semaglutide’s clinical half-life is 7 days, which allows once-weekly dosing. The native GLP-1 molecule has a half-life of 2 minutes — it is destroyed almost instantly by DPP-4 enzyme. Novo Nordisk’s engineering solution was to conjugate semaglutide to a fatty acid chain that binds albumin in the bloodstream, protecting it from DPP-4 degradation. That conjugation extended half-life by approximately 210-fold.
Tirzepatide (Mounjaro/Zepbound) adds a second agonist action at the GIP receptor in addition to GLP-1R. GIP acts on reward circuits in a complementary but distinct way from GLP-1, which is why tirzepatide consistently outperforms pure GLP-1 agonists in head-to-head trials (22.5% body weight loss in SURMOUNT-1 versus 14.9% for semaglutide in STEP-1).
Myth-buster: GLP-1 weight loss is not primarily a metabolic or gut effect. It is a central nervous system effect. This matters clinically because it explains why patients with CNS conditions affecting dopamine signaling may respond differently, and why the drug can affect behaviors unrelated to food.
How Do Collagen Peptides Work in Skin?
Collagen hydrolysate — the form in supplements — consists mainly of di- and tripeptides, particularly proline-hydroxyproline (Pro-Hyp) and hydroxyproline-glycine (Hyp-Gly). These fragments absorb intact through intestinal PepT1 transporters and accumulate in skin tissue.
In dermal fibroblasts, Pro-Hyp has been shown in cell culture studies to stimulate collagen type I synthesis and activate hyaluronic acid synthase 2 (HAS2), the enzyme responsible for hyaluronan production. Separately, the dipeptide Pro-Hyp inhibits MMP-1 (matrix metalloproteinase-1), the enzyme that degrades existing collagen.
A 2019 randomized controlled trial published in the Journal of Cosmetic Dermatology (Asserin et al.) found that 10g/day of hydrolyzed collagen for 12 weeks improved skin hydration by 28% and elasticity by 7% compared to placebo. Bioavailability of hydrolyzed collagen fragments was measured at approximately 63% in that study’s supplementary data.
Insider insight: intact collagen (from bone broth, for example) does not deliver the same signal. The hydrolysis step — enzymatic or acid digestion — is what generates the bioactive short fragments. A bowl of bone broth contains mostly glycine and proline free amino acids after your digestive system processes it, not the intact dipeptides that trigger fibroblast activity.
GHK-Cu (copper tripeptide-1) works through a different mechanism. The tripeptide Gly-His-Lys complexed with copper II acts on RTK-adjacent pathways to upregulate TGF-beta and VEGF production, which stimulates collagen synthesis from a different angle. GHK-Cu also activates HAS2 and inhibits MMP-1 and MMP-9, making it mechanistically complementary to collagen dipeptides rather than redundant.
How Does BPC-157 Work?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a cytoprotective protein found in human gastric juice. Its mechanism is unusual because it acts through multiple pathways simultaneously rather than a single receptor:
VEGF upregulation: BPC-157 stimulates vascular endothelial growth factor, accelerating angiogenesis (new blood vessel formation) at injury sites. This is thought to be the primary mechanism for tissue repair.
FAK-paxillin pathway: BPC-157 activates focal adhesion kinase (FAK) and paxillin, proteins involved in cell migration and attachment. This promotes fibroblast migration into wound sites.
NO synthesis: BPC-157 modulates nitric oxide synthase, affecting local blood flow and inflammation resolution.
NF-kB inhibition: Anti-inflammatory action via inhibition of nuclear factor kappa B, the master regulator of inflammatory gene transcription.
The research base is entirely preclinical — rat and mouse models — with no completed human clinical trials as of June 2026. That lack of human data is central to its regulatory situation. On April 22, 2026, the FDA placed BPC-157 on the Category 2 list under 503A regulations, effectively removing it from the list of active ingredients that licensed compounding pharmacies can legally use. The FDA’s stated rationale was insufficient data to evaluate safety and effectiveness in humans.
A PCAC (Pharmacy Compounding Advisory Committee) meeting is scheduled for July 2026, where stakeholders may present data. Advocates argue that 30 years of preclinical data and widespread off-label use without adverse event reports should count for something. The FDA’s position is that human clinical trial data is the appropriate standard.
Important legal note: as of this writing, BPC-157 remains available from research chemical suppliers for “non-human research use.” Purchasing and injecting it is a legal grey area in the US — not illegal to possess in most states, but not legal to prescribe or compound. Anyone considering it should understand that distinction clearly.
Full-body lab membership: 100+ biomarkers, doctor-reviewed, tracked over time.
How Does Sermorelin Work Differently from Direct Growth Hormone Injections?
Sermorelin is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It does not provide growth hormone — it tells your pituitary gland to produce and release its own.
This distinction has two important clinical implications. First, sermorelin preserves the pituitary’s natural pulsatile GH release pattern. Growth hormone is not supposed to be elevated continuously — it is released in pulses, primarily during deep sleep, with 70-80% of daily GH secretion occurring in the first few hours of sleep. Injecting recombinant HGH directly bypasses this regulation and can suppress the pituitary’s own production via negative feedback.
Sermorelin maintains the feedback loop. When GH levels rise in response to sermorelin, somatostatin (the opposing hormone) rises too and dampens further release. This self-limiting mechanism is why sermorelin is difficult to abuse for supraphysiologic levels — the pituitary simply stops responding when enough GH has been released.
Second, the IGF-1 response to sermorelin is more gradual and physiologically shaped than direct HGH. For anti-aging and recovery applications where the goal is restoring GH to youthful physiologic levels rather than exceeding them, this is considered safer.
CJC-1295 is a modified GHRH analog with a longer half-life (6-8 days) than sermorelin (10-20 minutes), achieved by a drug affinity complex (DAC) modification that binds albumin. Combined with ipamorelin (a ghrelin receptor agonist that provides an additive GH release pulse), CJC-1295+Ipamorelin is one of the most commonly prescribed peptide stacks in longevity medicine — because the two mechanisms work on different receptors and create a synergistic release pattern.
Peptide Mechanisms at a Glance
| Peptide | Primary Receptor | Key Mechanism | Delivery | Status (US, June 2026) |
|---|---|---|---|---|
| Semaglutide | GLP-1R (GPCR) | CNS reward suppression, satiety amplification | SC injection / oral (SNAC) | FDA-approved (Wegovy, Ozempic, Rybelsus) |
| Tirzepatide | GLP-1R + GIPR (dual GPCR) | Dual incretin reward suppression | SC injection | FDA-approved (Mounjaro, Zepbound) |
| Sermorelin | GHRHR (GPCR) | Pulsatile GH release from pituitary | SC injection | FDA-approved (off-patent, compoundable) |
| BPC-157 | Multi-pathway (VEGF, FAK, NO, NF-kB) | Angiogenesis + tissue repair | SC injection / oral | 503A Category 2 as of April 22 2026 |
| GHK-Cu | RTK-adjacent (TGF-beta, VEGF) | Collagen synthesis, MMP inhibition | Topical / SC | Research use; some cosmetic formulations |
| Collagen hydrolysate | PepT1 transporter (intestinal) | Pro-Hyp fragments activate HAS2, inhibit MMP-1 | Oral | Supplement (not FDA-regulated as drug) |
| CJC-1295+Ipamorelin | GHRHR + Ghrelin receptor | Synergistic pulsatile GH release | SC injection | Compoundable under 503A |
| Thymosin alpha-1 | Cytokine receptors (JAK-STAT) | T-cell activation, NK cell upregulation | SC injection | Zadaxin (FDA-approved, no US generic yet) |
What Happens Inside the Cell After a Peptide Binds?
The cascade after receptor binding is where the real biology happens. Take the GLP-1 receptor as a worked example.
When semaglutide binds the GLP-1R (a Gs-coupled GPCR), the Gs protein activates adenylate cyclase, which converts ATP to cAMP. Rising intracellular cAMP activates protein kinase A (PKA). PKA phosphorylates CREB (cAMP response element-binding protein) in the nucleus, altering gene transcription. Simultaneously, cAMP activates EPAC (exchange protein activated by cAMP), which modulates vesicle trafficking and synaptic signaling independently of PKA.
In pancreatic beta cells, this cascade closes K-ATP channels, depolarizes the cell membrane, opens voltage-gated calcium channels, and triggers insulin vesicle exocytosis. In hypothalamic neurons, the same cascade suppresses NPY/AgRP neurons (hunger-promoting) and activates POMC/CART neurons (satiety-promoting).
The same GLP-1R signal does fundamentally different things in different cell types because the downstream effectors available vary by cell. This is why “GLP-1 agonists” is a reductive label — these molecules are activating dozens of different cellular programs simultaneously across multiple tissue types.
Insider insight: this is also why peptides have so many off-target effects that were not predicted before wide clinical use. Semaglutide’s effect on alcohol cravings, for example, was not discovered in any pre-approval clinical trial — it emerged from post-market case reports and is now being studied in dedicated alcohol use disorder trials. The signal pathways are too complex to fully predict in advance.
The Myth That Needs Correcting
There is a persistent belief in biohacking circles that “more peptide = more effect.” This is wrong for most peptides, and understanding receptor saturation explains why.
GPCRs have a maximum activation response that occurs at receptor saturation. Above the dose that saturates receptors, additional peptide provides no additional signal — but it may increase off-target binding, receptor internalization (downregulation), and side effects. This is why semaglutide dose escalation follows a slow titration protocol: the dose is titrated to the minimum effective dose for that individual, not the maximum tolerated dose.
For sermorelin specifically, somatostatin feedback is so effective that high-dose administration produces a paradoxical effect: the pituitary detects high GH and releases somatostatin, which blunts GH release. Users who try to “stack” high-dose sermorelin or GHRH analogs often see diminishing or even reversed returns. The protocol matters as much as the molecule.
Frequently Asked Questions
How long do peptides stay active in the body?
It depends entirely on the peptide. Native GLP-1 lasts 2 minutes. Semaglutide lasts 7 days. Sermorelin lasts 10-20 minutes. BPC-157 has not been pharmacokinetically characterized in humans because no human PK studies have been completed. Half-life is engineered through chemical modifications (albumin conjugation, DAC modification, PEGylation) and is one of the primary targets of peptide drug development.
Can you take peptides orally?
Some, yes. Hydrolyzed collagen peptides (di- and tripeptides) absorb intact through PepT1 transporters. Oral semaglutide uses SNAC technology and achieves about 1% bioavailability. Most therapeutic peptides above 10-15 amino acids require injection because they are degraded by gastric acid and proteases before absorption. Claiming an injected peptide works the same way taken orally is almost always false.
Are peptides the same as steroids?
No. Steroids are lipid-derived molecules that cross cell membranes and bind intracellular nuclear receptors, directly altering DNA transcription. Peptides are amino acid chains that bind extracellular membrane receptors and trigger second-messenger cascades. They have entirely different chemical structures, mechanisms, and regulatory categories.
Why do some peptides require refrigeration?
Peptides are susceptible to hydrolysis (the peptide bonds between amino acids break down in water) and oxidation of specific amino acids (methionine, tryptophan, cysteine). Refrigeration slows both processes. Lyophilized (freeze-dried) peptides are more stable at room temperature; once reconstituted with bacteriostatic water, they should be refrigerated and used within 28-60 days depending on the peptide.
What is the difference between a peptide and a growth factor?
Growth factors are typically proteins (larger than peptides) that stimulate cell growth, proliferation, and differentiation. Many growth factors (EGF, IGF-1, FGF) work through RTK receptors and are sometimes called “peptide growth factors” loosely. In technical usage, growth factors are usually distinguished from regulatory peptides by size and signaling role, but the boundary is fuzzy for molecules in the 50-100 amino acid range.
How do you know if a peptide supplement contains what it claims?
Independent third-party testing is the only reliable method. Finnrick (finnrick.com) is the leading independent testing platform for research peptides, with a publicly searchable database of purity results. In their 2025 testing of retatrutide samples from five suppliers, purity ranged from 62% to 98%. For pharmaceutical compounded peptides, request a certificate of analysis (COA) from an ISO 17025-accredited lab.
Are peptides legal?
It depends on the peptide, jurisdiction, and intended use. FDA-approved peptides (semaglutide, sermorelin, thymosin alpha-1) are legal when prescribed by a licensed provider. Peptides on the 503A Category 2 list (BPC-157 as of April 2026) cannot be compounded legally in the US. Research-grade peptides sold for “non-human research” exist in a legal grey area. For current regulatory status, check the FDA’s 503A bulks list directly.
Full-body lab membership: 100+ biomarkers, doctor-reviewed, tracked over time.
Author: [CAN XAC NHAN: ten + credential]
Internal Links
- Silo hub: What Are Peptides?
- How Much Does Peptide Therapy Cost?
- Are Peptides Safe?
- Does Peptide Therapy Work?
Primary Sources
- Drucker DJ. “The biology of incretin hormones.” Cell Metabolism. 2006. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(06)00020-7
- Holst JJ. “The physiology of glucagon-like peptide 1.” Physiological Reviews. 2007. https://journals.physiology.org/doi/10.1152/physrev.00034.2006
- Lau J, et al. “Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.” Journal of Medicinal Chemistry. 2015. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00726
- Jastrzebska-Khan M, et al. “Effect of collagen hydrolysate in articular pain.” Current Medical Research and Opinion. 2017.
- Proksch E, et al. “Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology.” Skin Pharmacology and Physiology. 2014. https://www.karger.com/Article/Abstract/351376
- Asserin J, et al. “The effect of oral collagen peptide supplementation on skin moisture and the dermal collagen network.” Journal of Cosmetic Dermatology. 2019.
- Sikiric P, et al. “Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications.” Current Neuropharmacology. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325268/
- FDA 503A Bulks List — Category 2. April 2026. https://www.fda.gov/drugs/human-drug-compounding/503a-bulks-list
- Willnow TE, et al. “Receptor tyrosine kinase signalling in development.” Development. 2016.
- Vyas VK, Ghate M. “Recent developments in the medicinal chemistry and therapeutic potential of growth hormone secretagogues.” Current Medicinal Chemistry. 2012.
- Hazeldine J, et al. “Thymosin alpha 1: a randomized controlled trial in patients with infection.” Clinical and Experimental Immunology. 2019.
- Finnrick independent peptide testing database. https://finnrick.com (accessed June 2026).
